| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
Renal Replacement Therapy |


*Renal Division, Baxter Healthcare Corporation, McGaw Park, Indiana;
Nephrology Division, Indiana University School of Medicine, Indianapolis, Indiana; and
Center for Biomedical Engineering, University of Kentucky, Lexington, Kentucky.
Address correspondence to Dr. William R. Clark, Hemodialysis Research Laboratory, Renal Division, Baxter Healthcare Corporation, Wishard Hospital/Myers Building D711, 1001 West 10th Street, Indianapolis, IN 46202. Phone: 317-613-2315, ext. 327; Fax: 317-613-2317; E-mail: clarkbi{at}baxter.com
Abstract
ABSTRACT. Low-molecular-weight proteins (LMWP) are now recognized as a distinct class of uremic toxins, and numerous compounds in this category have been identified. Dr. Henderson has spent much of his career investigating ways to enhance the removal of intermediate- and large-sized uremic retention molecules. As LMWP clearly fall under this category, it is fitting to provide a review of several aspects of this molecular class. Normal renal metabolism of LMWP is discussed along with the changes that occur during chronic renal insufficiency. The effect of end-stage renal disease on plasma LMWP concentrations is assessed. As examples of the potential uremic toxicity of this molecular class, leptin, adrenomedullin, and the compounds associated with increased susceptibility to infection are highlighted. Finally, an overview of LMWP removal mechanisms for both hemodialysis and the convective therapies is provided.
This article has been cited by other articles:
![]() |
A. Santoro, E. Ferramosca, E. Mancini, C. Monari, M. Varasani, L. Sereni, and M. Wratten Reverse mid-dilution: new way to remove small and middle molecules as well as phosphate with high intrafilter convective clearance Nephrol. Dial. Transplant., July 1, 2007; 22(7): 2000 - 2005. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Brodie and H. D. Humes Stem Cell Approaches for the Treatment of Renal Failure Pharmacol. Rev., September 1, 2005; 57(3): 299 - 313. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Ottonello, P. Gnerre, M. Bertolotto, M. Mancini, P. Dapino, R. Russo, G. Garibotto, T. Barreca, and F. Dallegri Leptin as a Uremic Toxin Interferes with Neutrophil Chemotaxis J. Am. Soc. Nephrol., September 1, 2004; 15(9): 2366 - 2372. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Saito, J. J. Kazama, N. Iino, K. Cho, N. Sato, H. Yamazaki, Y. Oyama, T. Takeda, R. A. Orlando, F. Shimizu, et al. Bioengineered Implantation of Megalin-Expressing Cells: A Potential Intracorporeal Therapeutic Model for Uremic Toxin Protein Clearance in Renal Failure J. Am. Soc. Nephrol., August 1, 2003; 14(8): 2025 - 2032. [Abstract] [Full Text] [PDF] |
||||
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673